ABT Stock Jumps 12% Since Q4 Earnings: Time to Invest in Abbott?

In 2024, Abbott Laboratories (ABT) faced industry-wide challenges that exerted pressure on its profit margins. Factors such as rising inflation, labor shortages and supply chain disruptions resulted in increased operational costs, contributing to margin pressure. However, the company’s strong pipeline and innovation-driven growth strategy have helped it maintain an uptrend in its stock performance. With new product launches and strategic market penetration, Abbott’s growth outlook for 2025 remains robust, r ...